ArticleJournal of thoracic disease2023

Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.

Chen Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.